TxCell move to CMO allows clinical trial to be restarted

Vials
Vials--Courtesy of the University of Michigan CC BY 2.0

TxCell, a French biotech that saw its clinical trial go off the rails when French regulators shut down its clinical manufacturing operation, has restarted the trial after turning production over to a contract manufacturer.

The company said Wednesday that it has received approval from EU regulators to restart its Phase IIb clinical trial with its lead product Ovasave in patients with moderate to severe Crohn’s disease that is resistant to other treatments. Part of the approval was based on the company moving manufacturing to MaSTherCell and the CMO having conducted a series of successful validation runs on the product.

TxCell hired the Belgian CMO last year to take on its clinical supplies and potentially commercial manufacturing for its lead candidate after regulators shut down TxCell’s pilot facility in Besançon, France, in June 2015 over mold issues. At the time the plant was closed, TxCell said it expected to make improvements and reopen its facility, but after a new CEO took over, it decided to go the CMO route.

Whitepaper

Simplify and Accelerate Drug R&D With the MarkLogic Data Hub Service for Pharma R&D

Researchers are often unable to access the information they need. And, even when data does get consolidated, researchers find it difficult to sift through it all and make sense of it in order to confidently draw the right conclusions and share the right results. Discover how to quickly and easily find, synthesize, and share information—accelerating and improving R&D.

Since then, the company has picked contract manufacturer PCT to handle its clinical supply manufacturing in the U.S.

- here’s the announcement

Related Articles:
CMO helps TxCell move forward with clinical supplies after pilot plant closed
Contract manufacturer PCT will handle TxCell production in U.S.
TxCell halts drug production, a decision made with French regulator



 

 

 

Read more on

Suggested Articles

Fujifilm has completed the first manufacturing facility in Japan to make drug-delivering liposomes to use for cancer fighting drugs it is developing.

Three Samsung execs face up to two years in jail for their roles in destroying data and documents at under-fire affiliate Samsung BioLogics.

The FDA has slapped a U.S. drug repackager, saying in a warning letter that its storage processes and equipment cleaning are not up to expectations.